🚀 Big news from the Maurice lab!
OutMARCH has secured an EIC Pathfinder grant to develop SureTACs, bispecific antibodies that degrade cancer driving membrane proteins, including previously undruggable targets. A new precision strategy to overcome therapy resistance in cancer. Thread 👇
